NASDAQ:BIIBBiogen Stock Price, Forecast & News

Biogen's stock was trading at $294.25 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, BIIB stock has decreased by 5.3% and is now trading at $278.70. View which stocks have been most impacted by Coronavirus.

31 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biogen in the last year. There are currently 5 sell ratings, 17 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Biogen.

Biogen is scheduled to release its next quarterly earnings announcement on Tuesday, July 28th 2020. View our earnings forecast for Biogen.

Biogen Inc (NASDAQ:BIIB) issued its quarterly earnings data on Wednesday, April, 22nd. The biotechnology company reported $9.14 EPS for the quarter, topping analysts' consensus estimates of $7.73 by $1.41. The biotechnology company had revenue of $3.53 billion for the quarter, compared to the consensus estimate of $3.41 billion. Biogen had a net margin of 40.76% and a return on equity of 49.22%. Biogen's revenue for the quarter was up 1.3% on a year-over-year basis. During the same quarter in the prior year, the business posted $6.98 EPS. View Biogen's earnings history.

Biogen announced that its board has authorized a share buyback plan on Monday, December 23rd 2019, which allows the company to repurchase $5,000,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization allows the company to reacquire shares of its stock through open market purchases. Stock repurchase plans are usually a sign that the company's board of directors believes its stock is undervalued.

31 equities research analysts have issued 1-year price objectives for Biogen's stock. Their forecasts range from $228.00 to $410.00. On average, they anticipate Biogen's stock price to reach $309.63 in the next year. This suggests a possible upside of 11.1% from the stock's current price. View analysts' price targets for Biogen.

Media coverage about BIIB stock has trended somewhat negative on Thursday, according to InfoTrie Sentiment Analysis. The research firm ranks the sentiment of media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Biogen earned a news sentiment score of -1.6 on InfoTrie's scale. They also gave news stories about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company's share price in the next several days. View the latest news about Biogen.

Some companies that are related to Biogen include Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Celgene (CELG), Regeneron Pharmaceuticals (REGN), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Immunomedics (IMMU), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Biogen investors own include Gilead Sciences (GILD), NVIDIA (NVDA), Netflix (NFLX), Alibaba Group (BABA), Tesla (TSLA), Amgen (AMGN), Walt Disney (DIS), Celgene (CELG), Micron Technology (MU) and Intel (INTC).

Biogen trades on the NASDAQ under the ticker symbol "BIIB."

Biogen's stock is owned by a number of institutional and retail investors. Top institutional investors include Envestnet Asset Management Inc. (0.11%), DNB Asset Management AS (0.09%), State of Alaska Department of Revenue (0.04%), Cullinan Associates Inc. (0.01%), Livforsakringsbolaget Skandia Omsesidigt (0.01%) and Thomasville National Bank (0.01%). Company insiders that own Biogen stock include Alexander J Denner, Brian S Posner, Michael D Ehlers, Michel Vounatsos, Robert W Pangia and Stephen A Sherwin. View institutional ownership trends for Biogen.

BIIB stock was sold by a variety of institutional investors in the last quarter, including Thomasville National Bank, Municipal Employees Retirement System of Michigan, Richard P Slaughter Associates Inc, Triangle Securities Wealth Management, IBM Retirement Fund, and Cottage Street Advisors LLC. Company insiders that have sold Biogen company stock in the last year include Brian S Posner, and Stephen A Sherwin. View insider buying and selling activity for Biogen.

BIIB stock was purchased by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue, Envestnet Asset Management Inc., Cullinan Associates Inc., Patton Fund Management Inc., 6 Meridian, DNB Asset Management AS, Polianta Ltd, and Livforsakringsbolaget Skandia Omsesidigt. Company insiders that have bought Biogen stock in the last two years include Alexander J Denner, and Michel Vounatsos. View insider buying and selling activity for Biogen.

Shares of BIIB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of BIIB stock can currently be purchased for approximately $278.70.

Biogen has a market capitalization of $45.48 billion and generates $14.38 billion in revenue each year. The biotechnology company earns $5.89 billion in net income (profit) each year or $33.57 on an earnings per share basis. Biogen employs 7,400 workers across the globe.

The official website for Biogen is www.biogen.com.

Biogen's mailing address is 225 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at 617-679-2000 or via email at [email protected]